Evidence map›Paper›PMID 42137264›Full record

ArticleMolecular therapy. Advances2026

Plasmid DNA vaccines encapsulated in lipid nanoparticles elicit STING-dependent type 1 interferon release.

Jena E Moseman, Hannah M Brinkman, Joshua A Choe, Daeun Shim, Jacobus C Burger, Francesca Ferraresso, Ichwaku Rastogi, Christian J Kastrup, William L Murphy, Douglas G McNeel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jena E MosemanDepartment of Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.
Hannah M BrinkmanDepartment of Orthopedics and Rehabilitation, University of Wisconsin-Madison, Madison, WI, USA.
Joshua A ChoeDepartment of Orthopedics and Rehabilitation, University of Wisconsin-Madison, Madison, WI, USA.
Daeun ShimDepartment of Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.
Jacobus C BurgerDepartment of Orthopedics and Rehabilitation, University of Wisconsin-Madison, Madison, WI, USA.
Francesca FerraressoVersiti Blood Research Institute, Versiti Wisconsin, Milwaukee, WI 53226, USA.
Ichwaku RastogiDepartment of Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.
Christian J KastrupVersiti Blood Research Institute, Versiti Wisconsin, Milwaukee, WI 53226, USA.
William L MurphyDepartment of Orthopedics and Rehabilitation, University of Wisconsin-Madison, Madison, WI, USA.
Douglas G McNeelDepartment of Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.

Funding

NRSA Training CoreTL1TR002375 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI Vivek Prabhakaran · 2017 to 2026
$8.4M
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
Integrated Training For Physician-ScientistsT32GM140935 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Anna Huttenlocher, Jeniel E Nett · 2021 to 2026
$6.5M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
Mineral Coated Microparticles for Stabilization and Delivery of Complexed mRNA for Healing of Long Bone DefectsF30AG077748 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI CHOE, JOSHUA ALAN · 2022 to 2024
$87k
NCATS NIH HHS TL1 TR002375NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIA NIH HHS F30 AG077748NIDA NIH HHS 75N95020D00005NIGMS NIH HHS T32 GM140935NIH HHS 75N93023D00005NIH HHS 75N99020D00005
6 · The paper itself

Abstract

Plasmid DNA vaccines have excellent safety, stability, and tolerability profiles, making them a popular choice for cancer immunotherapy. However, challenges in targeted delivery to professional antigen-presenting cells, and the requirement for nuclear translocation of DNA, have limited the immunogenicity of this approach. The implementation of ionizable lipid nanoparticles (LNPs) for mRNA vaccines has enabled robust cellular and humoral immunity profiles after immunization. Here, we sought to determine whether encapsulation of plasmid DNA in ionizable LNP could improve DNA vaccine efficacy. Using

Indexed as

cancer immunotherapylipid nanoparticlesmRNA-LNPnucleic acidspDNA-LNPSTINGtype I interferonvaccine

Identifiers

PMID42137264
PMCPMC13148951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.